Mortality in Greenlanders with chronic hepatitis B virus infection.


Journal

Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672

Informations de publication

Date de publication:
06 2022
Historique:
revised: 02 03 2022
received: 30 12 2021
accepted: 07 03 2022
pubmed: 1 4 2022
medline: 14 5 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

In-depth reviewing of all medical records and clinical databases concluded a 7-year shorter lifespan among Greenlanders infected with hepatitis B virus (HBV) compared with non-infected. Mortality did not associate with liver disease or any other specific disease entity. A possible mechanism for the reduced lifespan is subclinical inflammation that may be augmented by chronic viral infection. We hypothesized that chronic HBV infection contributes to this process causing a reduced life span. We added measurement of two markers of inflammation to the 10-year follow-up on our study of HBV among 50- through 69-years-old subjects in Greenland. The markers were YKL40 related to liver disease and hsCRP as a global marker of inflammation. Survival was evaluated using Cox regression with time until death entered as dependent variable and age, sex, smoking, alcohol intake, BMI, the presence of HBsAg and one marker of inflammation as explanatory variables. Forty-eight percent of participants with chronic HBV infection were alive after 10 years compared with 65% of participants without infection (p = 0.003). Survival associated with age (p < 0.001), BMI (p = 0.003) and both YKL40 and hsCRP (both, p < 0.001). Harbouring HBV influenced 10-year survival in the Cox regression after adjusting for age, sex, BMI, smoking, alcohol intake and inflammation. In conclusion, chronic low-grade inflammation and being infected with HBV were independent markers of mortality in otherwise healthy subjects. Thus, the 7-year shorter lifespan among Greenlanders with chronic HBV infection seems related to the long-lasting infection. Our findings call for caution in perceiving a chronic infection as benign.

Identifiants

pubmed: 35357746
doi: 10.1111/jvh.13673
pmc: PMC9321676
doi:

Substances chimiques

Chitinase-3-Like Protein 1 0
DNA, Viral 0
Hepatitis B Surface Antigens 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-437

Informations de copyright

© 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

Références

J Am Geriatr Soc. 2013 Apr;61(4):512-8
pubmed: 23452127
J Viral Hepat. 2022 Jun;29(6):432-437
pubmed: 35357746
Front Cardiovasc Med. 2018 Feb 22;5:12
pubmed: 29564335
Nat Rev Immunol. 2013 Dec;13(12):875-87
pubmed: 24157572
Scand J Gastroenterol. 2008 Mar;43(3):334-43
pubmed: 18266176
Gastroenterology. 2020 Aug;159(2):652-664
pubmed: 32302614
J Am Geriatr Soc. 2010 Feb;58(2):234-41
pubmed: 20370857
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Curr Opin Immunol. 2012 Aug;24(4):507-11
pubmed: 22541724
Crit Rev Clin Lab Sci. 2016 Dec;53(6):396-408
pubmed: 27187575
Scand J Gastroenterol. 2012 Jun;47(6):692-701
pubmed: 22229496
Scand J Gastroenterol. 2006 Apr;41(4):445-50
pubmed: 16635913
Acta Paediatr Scand. 1986 Nov;75(6):1010-6
pubmed: 3564958
J Viral Hepat. 2013 Feb;20(2):122-30
pubmed: 23301547
Am J Clin Nutr. 2005 Mar;81(3):656-63
pubmed: 15755836
J Am Geriatr Soc. 2002 Apr;50(4):638-44
pubmed: 11982663
Br J Nutr. 2013 Jul 14;110(1):50-7
pubmed: 23182389
J Am Coll Cardiol. 2017 Aug 22;70(8):913-922
pubmed: 28818200
J Viral Hepat. 2013 Dec;20(12):890-6
pubmed: 24304459
Infection. 2018 Jun;46(3):385-393
pubmed: 29600444
Atherosclerosis. 2013 Jun;228(2):496-501
pubmed: 23591413
Int J Circumpolar Health. 2013 Aug 05;72:
pubmed: 23986904
Mech Ageing Dev. 2016 Sep;158:27-37
pubmed: 26773975
Lancet Diabetes Endocrinol. 2018 Dec;6(12):944-953
pubmed: 30389323
PeerJ. 2017 Aug 31;5:e3757
pubmed: 28875087
World J Hepatol. 2015 May 28;7(9):1265-71
pubmed: 26019742
Eur J Endocrinol. 2004 Dec;151(6):735-40
pubmed: 15588240

Auteurs

Henrik B Krarup (HB)

Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Karsten F Rex (KF)

Department of Internal Medicine, Queen Ingrid's Hospital, Nuuk, Greenland.
Arctic Health Research Centre, Aalborg University Hospital, Aalborg, Denmark.

Stig Andersen (S)

Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Department of Internal Medicine, Queen Ingrid's Hospital, Nuuk, Greenland.
Arctic Health Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Greenland Institute for Health Research, Ilisimatusarfik, Greenland University, Nuuk, Greenland.
Department of Geriatric Medicine, Aalborg University Hospital, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH